索拉非尼对血管内皮生长因子促大鼠肝肿瘤的抑制效果

发布时间：2018-06-14 08:56

本文选题：原位种植性肝癌 + 血管内皮生长因子　；参考：《中山大学学报(医学科学版)》2017年03期

【摘要】：【目的】探索sorafenib(索拉非尼)在不同干预时机中对血管内皮生长因子(VEGF)促瘤效应的抑制作用。【方法】将50只SD大鼠肝脏接种Wakler256肿瘤细胞形成的裸鼠皮下瘤块,10 d后行MR扫描,选取建模成功的40只SD大鼠随机分成4组,每组10只:A组,对照组,仅注射VEGF;B组,sorafenib先于VEGF 72 h导入组;C组,sorafenib与VEGF同时导入组;D组,sorafenib后于VEGF 72 h导入组。观察并比较4组实验动物肿瘤的生长及中位生存时间。待实验动物死亡后,采用免疫组织化学法检测各组大鼠肝肿瘤的VEGF的表达。【结果】服用sorafenib 10 d后,MR显示各组大鼠肝脏肿瘤明显增大,sorafenib组肿瘤大小小于对照组(5.40 cm),具有统计学意义(P0.05)。四组实验动物中位生存时间分别是(19.6±1.8)d、(31.2±7.0)d、(27.4±4.9)d、(26.5±4.6)d。服用sorafenib组大鼠生存时间明显长于对照组(P0.05)。将死亡实验大鼠进行HE染色及免疫组织化学检查,四组实验动物的VEGF值分别为88.3±13.6、42.8±8.0、71.9±15.7、73.6±13.7,sorafenib组与对照组数值差异具有明显统计学意义(P0.05),且不同sorafenib组之间数值差异较大。【结论】Sorafenib能延长肝肿瘤大鼠的生存时间,减少肿瘤血管生成。Sorafenib服用时间早于VEGF一过性升高前的生存获益明显好于VEGF升高后服用。
[Abstract]:[objective] to investigate the inhibitory effect of sorafenibil on vascular endothelial growth factor (VEGF) in different intervention time. [methods] 50 SD rats were inoculated with subcutaneous tumor cells of Wakler256 tumor cells in nude mice for 10 days. Forty SD rats were randomly divided into 4 groups, 10 rats in each group and 10 rats in control group. Only group VEGFN B was injected with sorafenib before VEGF 72 h in group C and group C was introduced with VEGF at the same time as group D and then group D was injected with sorafenib at 72 h before VEGF was introduced at 72 h. The growth and median survival time of tumor in 4 groups were observed and compared. After the death of the experimental animal, Immunohistochemical method was used to detect the expression of sorafenib in the liver tumors of rats in each group. [results] after 10 days of administration of sorafenib, Mr showed that the tumor size of the group was significantly larger than that of the control group (5.40 cm ~ (-1), which had statistical significance (P 0.05). The median survival time of the experimental animals in the four groups was 19.6 卤1.8g / d, 31.2 卤7.0g / d, 27.4 卤4.9g / d, 26.5 卤4.6 / d, respectively. The survival time of sorafenib group was longer than that of control group (P 0.05). The death rats were stained with HE and immunohistochemistry. The VEGFvalues of the experimental animals in the four groups were 88.3 卤13.6 卤42.8 卤8.0 卤71.9 卤15.77.73.6 卤13.7 respectively, and there were significant differences between the sorafenib groups and the control group. [conclusion] Sorafenib can prolong the survival time of the rats with liver tumor, and the difference is significant among the four groups. [conclusion] Sorafenib can prolong the survival time of the rats with liver tumor. The survival benefit of decreasing tumor angiogenesis. Sorafenib was significantly better than that of VEGF.
【作者单位】：中山大学附属第一医院放射介入科;
【基金】：吴阶平医学基金(320.6750.14800)
【分类号】：R735.7

【相似文献】